With 14.68 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.56 million shares. The 52-week range on GENI shows that it touched its highest point at $11.40 and its lowest point at $5.03 during that stretch. It currently has a 1-year price target of $12.33. Beta for the stock currently stands at 1.97.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GENI was down-trending over the past week, with a drop of -3.66%, but this was up by 19.82% over a month. Three-month performance surged to 10.97% while six-month performance rose 53.58%. The stock gained 100.00% in the past year, while it has gained 21.62% so far this year. A look at the trailing 12-month EPS for GENI yields -0.28 with Next year EPS estimates of 0.15. For the next quarter, that number is 0.01. This implies an EPS growth rate of 113.46% for this year and 311.16% for next year.
Float and Shares Shorts:
At present, 239.82 million GENI shares are outstanding with a float of 216.07 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GENI since 5 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.13811 being high and -$0.14387 being low. For GENI, this leads to a yearly average estimate of -$0.14082.
